1. Introduction {#s0005}
===============

Drug-related investigations have long shifted from just the discovery and synthesis of new and potent molecules towards the development of effective drug formulations or delivery systems which are actually more crucial and directly related to the desired pharmacotherapeutic efficacy within the body ([@b0205]). Besides, the actual design of the delivery system and its mode of application significantly impact in vivo pharmacokinetics, cell level uptake, tissue distribution, metabolism and excretion, clearance and overall adverse effects which all contribute towards the overall efficacy of the bioactive agent ([@b0205], [@b0290], [@b0310]). Despite continuous research advancements, optimal delivery of drugs remains a key challenge especially with the limitation associated with understanding biological barriers which led to a significant increase in research effort focused on the fabrication of novel biomaterials that can positively transform drug delivery efforts ([@b0205]). A biomaterial can be referred to as a non-drug matter, surface or construct that is capable of interacting with biological systems ([@b0570]). They can be derived from natural sources or synthesized and are often composed of various materials such as polymers, metals, glass, ceramic etc. and are required to be biocompatible but not necessarily biodegradable depending on their respective applications ([@b0240], [@b0360], [@b0570]).

Polymeric biomaterials have significantly impacted our day to day living. They play major roles in the food and beverages, clothing, automobile, packaging, water purification, sporting etc. industries ([@b0060], [@b0310], [@b0600]). They are macromolecules that have been extensively explored within the pharmaceutical and medical spheres as design templates for delivery systems containing drugs or biologicals. This is attributable to their exceptionally superior physical, chemical and mechanical properties that have completely changed the face of disease prophylaxis and therapy ([@b0205], [@b0310], [@b0570]). They have been employed in the development of a wide selection of smart delivery architectures such as nano/micro structures, liposomes, lipid-polymer platforms, stimulus responsive systems, implants, colloids, hydrogels, prolonged release systems, targeted delivery templates capable of eliciting varying functionalities and properties that make them desirable for biomedical applications. With bioactive delivery systems based on polymeric biomaterials, it is often possible to control/tailor bioactive release kinetics to meet specific therapeutic needs as opposed to conventional formulations which are usually less flexible, difficult to regulate and lack specificity ([@b0175], [@b0180], [@b0310]). These continuous advancements have directly impacted the significant growth in the number of polymer-based drug products that are under clinical trial investigations or been approved by regulatory bodies ([@b0205], [@b0310]).

Ethylcellulose is a partly O-ethylated cellulose ether polymeric biomaterial, typically hydrophobic in nature and widely applied within the biomedical and pharmaceutical industry for over half a century ([@b0625], [@b0445], [@b0725]). It is commercially produced with different viscosity grades keeping the variant ethoxy content within strict specification range for all types ([@b0445]). The various ethylcellulose types, usually distinguished by their nominal viscosities, molecular weights and ethoxy substitutions, are collectively referred to as "Premium Ethylcellulose Polymers", commercially marketed under the trade name Ethocel^TM^ ([@b0175], [@b0180], [@b0445]) and may contain suitable antioxidants ([@b0725]). Ethocel^TM^ polymers are typically tasteless, free-flowing, white to light tan-colored powder, odorless, non-caloric, and inert within the physiological environment ([@b0635], [@b0180]). Despite the continued trend towards the use of aqueous systems, the use of the ethylcellulose polymers is still growing. Ethylcellulose is biocompatible and approved by the United States Food and Drug Administration as a Generally-Recognized-As-Safe chemical substance that has demonstrated the potential to modulate and improve the physiological performance of bioactives through its frequent applications in controlled release solid dosage forms, granulation binders, film formers, coating materials, taste masking, implants, encapsulation (micro-, nano-, macro-), release modulator etc. ([@b0180], [@b0470], [@b0175], [@b0635]). This article therefore presents a scholarly survey of recent advances and future directions directly related to the functionalities of premium ethylcellulose polymeric biomaterials in the architecture of novel drug delivery systems intended for improving therapeutic and prophylactic outcomes. Key topics covered include ethylcellulose chemistry, synthesis, types, properties and recent developments on its application as an effective carrier for drugs and biologics.

2. Chemistry, synthesis and classification of ethylcellulose polymers {#s0010}
=====================================================================

Ethylcellulose is a linear polysaccharide derived from the naturally occurring polymer, cellulose and therefore possesses its polymeric backbone which is based on the repeating structure of ß-anhydroglucose ring having three reactive hydroxyl functional groups ([@b0145], [@b0625]). The substitutable hydroxyl groups of cellulose can partially or completely react with chemical compounds or moieties to form derivatives possessing useful properties ([@b0415]). Ethylcellulose is synthesized through the substitution of the cellulose hydroxyl moieties with ethoxyl groups ([@b0445]). Synthesis (etherification) steps involved include the dissolution of cellulose in sodium hydroxide aqueous solution (50%^w^/~w~ or greater) leading to the breakdown of the cellulose supramolecular structure resulting in the formation of an alkali cellulose and exposure of the cellulose hydroxyl group for reaction. Subsequently, ethyl chloride gas is added to the reaction medium leading to reaction with the alkalized cellulose yielding ethylcellulose plus two by-products namely sodium chloride and water ([Fig. 1](#f0005){ref-type="fig"}) ([@b0145], [@b0345], [@b0625]).Fig. 1Illustrations of: (a) chemical synthesis of ethylcellulose (adapted from [@b0625]) and (b) chemical backbone structures of cellulose and ethylcellulose (adapted from [@b0470]).

The elicited physical characteristics of ethylcellulose polymer types and their performances are primarily dependent on the degree of etherification or substitution (ethoxyl content) and molecular weight of the cellulosic backbone ([@b0145], [@b0345], [@b0445]). For instance, water solubility is achieved with degree of substitution (DS) between the range of 1.0--1.5 while solubility in organic solvents is achieved with DS values in the range of 2.2--2.6 ([@b0145], [@b0345]). Ethylcellulose commercial products usually have DS values ranging between 2.2 and 2.6 per anhydrous glucose unit and are marketed in a number of different viscosity grades. Usually, their viscosities increase as the polymeric backbone chain length increases and commercial grades are generally produced with differing viscosities while the ethoxyl content is strictly varied within standardized limits ([@b0625], [@b0445]). The pharmacopeial specification provides allowance for variations between 80 and 120% within highlighted nominal viscosity while ethoxy substitution is fixed within a range of 44--51% ([@b0445]). The quality of the manufacturing processes plays a major role in ensuring that these set limits are met. For example, Dow Chemical Company, a key global manufacturer of premium ethylcellulose polymers marketed as Ethocel^TM^ employ strict measures and thereby have products with viscosity and ethoxyl substitution variations of 90--110% and 48--49.5% respectively ([Table 1](#t0005){ref-type="table"}). Basically, six different ethylcellulose premium polymers are available specifically for pharmaceutical applications. These include Ethocel^TM^ standard 4, 7, 10, 20, 45 and100. In addition, standard Ethocel^TM^ 7, 10 and 100 premiums are available in the fine particle (FP) size also for pharmaceutical use ([Table 1](#t0005){ref-type="table"}). The particle size and distribution can potentially influence their performance (e.g. drug release, compressibility etc.) in relation to their pharmaceutical application ([@b0175]).Table 1Classes of commercially available premium ethylcellulose polymers ([@b0180], [@b0635]).Premium Ethylcellulose Polymers (Ethocel™)Solution viscosity (mPa.s)Ethoxyl content (%^w^/~w~)Maximum loss on drying (%^w^/~w~)Particle size (μm)43.0--5.548.0--49.52.0N/A76.0--8.048.0--49.52.0N/A7 FP6.0--8.048.0--49.52.0140.0 max, 5.0--15.0 mean109.0--11.048.0--49.52.0N/A10 FP9.0--11.048.0--49.52.0100.0 max, 3.0--15.0 mean2018.0--22.048.0--49.52.0N/A4541.0--49.048.0--49.52.0N/A10090.0--110.048.0--49.52.0N/A100 FP90.0--110.048.0--49.52.0150.0 max, 30.0--60.0 mean

3. General properties in relation to pharmaceutical and biomedical usefulness {#s0015}
=============================================================================

Premium ethylcellulose polymers (Ethocel™) can be described as white to light tan granular powders in physical appearance with bulk density and specific gravity of about 0.4 g/cm^3^ and 1.12--1.15 g/cm^3^ respectively ([@b0175], [@b0635]). Their glass transition temperatures range between 129 and 133 °C and they absorb minimal water from the atmosphere or even when inserted in water and the little absorbed water vapourizes readily ([@b0635]). Their attractive physical properties allow them to be used in a wide range of applications. They are considerably mechanically tough, thermoplastic, flexible (flexibility is retained when not plasticized and at temperatures as low as −40 °C), possess film forming properties, transparent which allows it application as coating agent in a variety of products ([@b0145], [@b0345]). Their excellent thermoplastic nature and ability to soften at 135--160 °C makes them versatile in pharmaceutical hot melt extrusion processes which aids desired drug release properties and improved bioavailability of especially poorly soluble bioactives ([@b0180]). They are thermally stable, have low flammability and can transmit light wavelengths between 2800 and 4000 Å ([@b0345]).

Ethocel^TM^ polymers are inert to alkalis of all strength and dilute acids and demonstrates compatibility with a wide variety of organic materials such as waxes, resins and plasticizers ([@b0345]). Their compatibility with organic materials have enhanced their use as film rheology modifiers, binding agents, adhesives and blends with other polymers and ceramic ([@b0145], [@b0195]). Ethylcellulose polymers are easy to use for solution applications because they are remarkably soluble a wide variety of solvents which include aromatic hydrocarbons, alcohols, ketones, chlorinated solvents esters amongst many others ([@b0175], [@b0625], [@b0640]). They are mostly readily soluble in solvents that have cohesive energies or solubility parameters that are closely related to theirs which differs depending on the degree of substitution of the respective Ethocel^TM^ polymer ([@b0105], [@b0625]). They are practically insoluble in glycerin, propylene glycol and water. Those that contain more than 46.5% of ethoxy groups are freely soluble in chloroform, 95% ethanol ethyl acetate, methanol and toluene while those that have less than 46.5% of ethoxy groups are freely soluble in chloroform, methyl acetate, tetrahydrofuran and in aromatic hydrocarbons plus ethanol mixtures ([@b0635]).

Ethylcellulose polymers are excellent film-formers and binders and are most frequently applied as coats or matrices in controlled release solid dosage formulations ([@b0470], [@b0175]). They usually form strong, hydrophobic and highly adhesive films which have also been used to improve tablet integrity, appearance and taste. They are versatile, often perform multiple functions in a single drug formulation and are characterized by very minimal batch-to-batch variations ([@b0175]). They often provide flexible diffusion barriers whose properties can be changed by the amount of pore-forming agents used, film thickness, solvent type and molecular weight of the ethylcellulose. These polymers are compatible with commonly employed coating techniques such as pan and fluidized bed ([@b0175]). Drug release kinetics through the ethylcellulose coatings is mostly controlled by the process of diffusion through the different layers. Research has shown that this is often a retarded process especially for formulations like tablets, capsules etc. with the exception of drug carriers characterized by larger surface areas such as pellets and granules in which cases, the release kinetics tend to be significantly more rapid. Besides, drug release from formulations such as ethylcellulose coated microcapsules may also be a function of the capsular wall thickness in addition to the surface area ([@b0235], [@b0475], [@b0635], [@b0800], [@b0810]).

Solutions of ethylcellulose in aromatic hydrocarbons are usually highly viscous except for low concentration solutions. In contrast, ethylcellulose dissolved in ethanol or methanol produce lower viscosity solution with poor film forming capabilities for practical applications. A mixture of these two solvent categories are reported to yield ethylcellulose solutions typified by their low viscosities and good film forming strength. Lower molecular weight aliphatic esters and ketones on the other hand yield ethylcellulose solutions with relatively low viscosities that produce films with good strength and elongation properties ([@b0625]).

They are susceptible to oxidative degradation in the presence of sunlight or ultra violet light at increased temperatures. This is often averted by the use of light absorbing (230--340 nm) antioxidants and chemical additives. Best storage conditions are usually less than 32 °C (90°F) in a dry area away from all heat sources. They are combustible, should not be stored near oxidizing agents such as peroxided and are known to be incompatible with paraffin and microcrystalline waxes. Ethylcellulose powders may irritate the eye and appropriate personal protective equipment (PPE) should be worn for protection.

They are highly compatible, globally acceptable polymeric material and comply with specifications of a number of regulatory bodies governing use in food, packaging, paper, adhesives and as pharmaceutical additives ([@b0170], [@b0180], [@b0470]). Their non-ionic and hydrophobic nature makes them non-reactive and are often described as inert in vivo and in vitro ([@b0145], [@b0170], [@b0175], [@b0345], [@b0470], [@b0625]). They exhibit good stability within pH 3--11 making them useful in both acidic and alkaline mixtures. They are essentially tasteless, odorless and non-caloric making them ideal candidates for pharmaceutical, food and personal care applications ([@b0170], [@b0625]). They are generally employed in oral and topical pharmaceutical formulation as well as food products. They are not metabolized following oral consumption and therefore does not usually add to body calories. They are often not recommended for use as excipients in parenteral products because they are not metabolized in the body and may be harmful to the kidneys. Irrespective, they are normally viewed as non-toxic, non-irritating and non-allergenic. The World Health Organization has not really specified an acceptable limit for daily intake because they are not considered to be harmful to health ([@b0635]). [Table 2](#t0010){ref-type="table"} presents a summary of the functions of ethylcellulose polymers in related drug delivery systems.Table 2Functions performed by Ethocel™ polymers in delivery systems.Type of drug delivery systemFunction of ethylcellulose premium polymersReferencesTablets, granules, pellets, microspheres, Varnishes, elastomersHydrophobic coating, taste masking, matrix former, binding agent, release extender[@b0235], [@b0460], [@b0135], [@b0250], [@b0805], [@b0765]Emulsions, colloids, dispersions, gels, Transungal systemsStability enhancer, viscosity and release modifier[@b0575], [@b0695]Transdermal systemsMechanical strengthener, extended release, cutaneous deposition, backing layer for prolonged release[@b0275], [@b0490]NanostructuresTaste masking, release retardant, increased encapsulation[@b0525], [@b0605], [@b0070], [@b0715]NanofiberFilament former[@b0775]ImplantsHydrophobicity promoter, mechanical strengthener[@b0780]

The appropriateness of a formed polymer film is dependent upon its apparent viscosity which is defined as the exhibited viscosity of a particular polymer concentration dissolved in a specific solvent at a known temperature. With the ethylcellulose polymers, viscosity levels are controlled by the polymer chain length which are dependent on the degree of polymerization or number of anhydroglucose units during synthesis. Ethylcellulose polymers exhibit a high glass transitioning point of about 140 °C and this is also related to the degree of substitution with a minimum level occurring at 2.55 (i.e. 48.5% ethoxy content). Like all polymers, the mechanical properties of ethylcellulose is dependent on their molecular weight. Gradual increase in their molecular weight increases their mechanical strength until a critical point when no further increase is recordable. This usually occurs at molecular weight of 7--8 × 10^4^ in commercially available film-coating polymers like ethylcellulose ([@b0625]). Visible or ultraviolet light has no discoloring effect on ethylcellulose. If not stabilized, these polymers are sensitive to oxidative degradation in the presence of sunlight or ultraviolet light and at increased temperatures. Therefore, heat and light stabilizers are often added, particularly in unpigmented formulations. Their average shelf life is two years and the appropriate storage conditions for Ethocel^TM^ polymer should not exceed 32 °C (90°F) in a dry and heat free area ([@b0170], [@b0625]).

4. Micro-structured drug carriers constructed from premium ethylcellulose polymers {#s0020}
==================================================================================

Ethylcellulose polymers are commonly applied as matrices or encapsulants for drug molecules to form micro-structured delivery systems which can be used as single entities, in injections, filled into capsule shell or incorporated into tablet matrices ([@b0270], [@b0410], [@b0470]). Their key functions are controlled release and taste masking and various processing techniques such as polymerization, spray drying, pan coating, fluid bed granulation, emulsification etc. are often employed ([@b0170], [@b0470], [@b0705], [@b0785]). Research has shown that ethylcellulose polymers have been incorporated within the design templates of various micro-configured delivery systems loaded with wide range pharmaceutical actives for application via different routes and pharmacotherapeutic purposes ([@b0185], [@b0190], [@b0255], [@b0320], [@b0480]). [Table 3](#t0015){ref-type="table"} summarizes examples of novel ethylcellulose-based micro-structures.Table 3Different drug delivery applications of ethylcellulose-based micro-structures.Micro-structured delivery systemsType; Function of EthylcelluloseOther additives; Preparation methodPharmaceutical active/drugPharmacotherapeutic indicationReferencesMicroparticle-in-orally disintegrating tabletEthylcellulose suspension (Surelease®); Drug release retardantLipid, magnesium aluminometasilicate; Melt adsorptionTamsulosin hydrochlorideSustained release[@b0130]MicrocapsuleEthylcellulose 10, 20, 100 cP; CarrierPolyethylene glycol, diethyl phthalate, triethyl citrate, petroleum ether, magnesium stearate; Emulsion solvent evaporation methodPropranolol hydrochlorideMatrix former and flexible release kinetics for different therapeutic applications[@b0015]MicroparticleEthocel™ standard 45; CoatingChitosan, Sodium tripolyphosphate; Ionotropic gelation/spray drying coupled with coacervation/solvent displacementDoxycycline hyclateControlled release mucoadhesive delivery systems for periodontal disease[@b0225]Occular microspongesEthylcellulose (degree of substitution 2.42--2.53); PlasticizerPluronic F-127, polyvinyl alcohol, toluene, dichloromethane, calcium chloride; *Quasi* emulsion solvent diffusionAcetazolamideEnhance therapeutic efficacy and reduction in systemic advers effect associated with oral acetazolamide[@b0500]Hollow microspheresEthylcellulose 10, 45 and 100 cP; Release extenderPolyvinyl pyrrolidone, ethanol, ether; Emulsification and vaccum dryingFelodipineImprovement of oral bioavailability[@b0580]MicroparticleEthocel^TM^ standard 7; Microparticle wall materialEudragit L100 and S100; Spray dryingIndole-3-aldehydeEnteric coating for targetted postbiotic small intestine delivery[@b0595]MicrospongeStandard ethylcellulose, Carrier system and release extenderDichloromethane, polyvinyl alcohol, xanthan gum; Modified double emulsification techniqueTacrolimusSustained release and improved immunosupressant activity[@b0785]Microparticle-in-extended release oral flexible tabletStandard ethylcellulose 10cP; Matrix formerHypromellose; GranulationCarbamazepineAid paediatric and geriatric compliance[@b0115]MicrospongesStandard ethylcellulose; PlasticizerEudragit S100, triethylcitrate, polyvinyl alcohol, sodium carboxy cellulose, magnesium stearate; Q*uasi* emulsion solvent diffusion techniquePrednisoloneColon specific drug delivery for efficacy enhancement[@b0350]Polymeric microspheresEthylcellulose 300 cP; Drug carrierEudragit L100-55;Oil-in-oil solvent evaporation techniqueIvabradine hydrochloridepH dependent drug release kinetics was achieved[@b0420]MicrosphereEthocel 20 cP; Release retardantNone; Precipitation and solvent evaporationRepaglinideSustained drug release and improved antidiabetic effect[@b0505]MicrocapsuleEthylcellulose 20 cP; EncapsulantPolyethyleneglycol 6000, ethylacetate; Emulsion-solvent diffusionMetoprolol succinateDrug encapsulation efficiency was significantly increased.[@b0690]Microparticles loaded with a drug/salt/complex formulationAqueous dispersion of ethylcellulose (Aquaacoat® ECD); Coat and release retardantSodium lauryl sulfate; Spray dryingMirabegronSustained release suspension for oral delivery minimizing side effects[@b0320]Microparticles-in-textile-based drug delivery systemEthylcellulose dispersion (Aquacoat® ECD), Release retardantPropylene glycol, colloidal silicon dioxide, triethyl citrate; Spray dryingNaproxenWearable delivery system for sustained anti-inflammatory activity in patients who cannot take oral of parenteral treatment[@b0045]MicromatricesEthocel™ 20 cP and Surelease; Sustained release, mechanical strengthenerEthanol; Spray dryingTheophyllineSustained release, improved absorption and bioavailability[@b0010], [@b0020]Microparticle-in-platformEthylcellulose NF20; release controlNone; Emulsification and solvent evaporationAminofluoride, sodium fluorideImprove oral delivery of fluoride increasing controlled localized supply and protection against dental caries[@b0150]Multifunctional layered microparticleEthocel™ 45 cP; Inert property, encapsulantEthanol; 3-fluid nozzle spray dryingDiclofenac sodiumSustained release and protection of bioactive[@b0510]Dermal polymeric microparticlesStandard ethylcellulose (ethoxy 48--49.5%); Encapsulating excipientPoly vinyl alcohol, poly (N-isopropylacrylamide), poly D,L lactide, poly D,L lactide coglycoside; Emulsification-solvent evaporationL-LevothyroxineIncreased drug encapsulation characterized by minimal leakage and transdermal permeation enhancement[@b0055]Microparticulated bioadhesive vaginal gelEthylcellulose 22 cP; Release decelerating polymerCarbopol, hydropropylmethylcellulose, toluene, ethanol; Dispersion and solvent evaporationZidovudineProlonged antiretroviral activity and convenient for patient use[@b0125]Modified-release microparticleEthylcellulose 22 cP; Release extenderCyclohexane, n-hexane, methanol; Phase separation by temperature transitionsTizanidine and tramadol hydrochlorideReduction of dosing frequency during adjuvant analgesic and muscle relaxant therapy[@b0005]Floating microparticlesStandard ethylcellulose; Floating enhancerEthanol, liquid paraffin, dichloromethane; Dispersion and solvent evaporationRanitidine hydrochlorideExtend release and gastroretention to improve the bioavailability of narrow window drugs[@b0430]

5. Nano-configured architectures based on premium ethylcellulose polymers {#s0025}
=========================================================================

Over the years, ethylocellulose polymers have been extensively applied in the development of bioactive loaded nano-structured delivery systems. Li and colleagues (2018) developed a ketoprofen-loaded dual-responsive nanofibre hybrid mat delivery system ([Fig. 2](#f0010){ref-type="fig"}(a)) based on a blend of ethylcellulose (6--9 mPa.s), poly (N-vinylcaprolactam) and Eudragit L100 using the twin-jet electrospinning technique. The developed nanosystem variants displayed uniformly distributed diameters ranging from 530 to 590 nm and they elicited both pH and thermal responsiveness as well as sustained release characteristics attributable to the hydrophobic nature of ethylcellulose. Besides, ethylcellulose was selected for this application because of its non-toxic, inert and hydrophobic properties ([@b0365], [@b0380]). Likewise, [@b0265] designed ketoprofen-loaded ethylcellulose (6--9 mPa.s) based nanofiber mesh system that elicited a desirable biphasic controlled release behaviour ([Fig. 2](#f0010){ref-type="fig"}(b)). Ketoprofen containing zero order, layered nanofiber delivery systems ([Fig. 2](#f0010){ref-type="fig"}(c)) were also developed using triaxial electrospinning coupled with ethylcellulose 6--9 mPa.s functioning as a filament-forming matrix within the outer, middle and inner cores of the working solutions with varied adjuvant contents ([@b0775]). Another study conducted by Illangakoon and team (2015) employed ethylcellulose 6--9 mPa.s as a 5-fluorouracil loaded core for the fabrication of an amorphous, monolithic fiber ([Fig. 2](#f0010){ref-type="fig"}(d)) by electrospinning.Fig. 2Select photomicrographs of ethylcellulose-based: (a) nanofibre hybrid mat delivery system (adapted from [@b0365], [@b0380]), (b) nanofiber mesh system (adapted from [@b0265]), (c) layered nanofiber delivery system (adapted from [@b0775]), (d) amorphous monolithic nanofiber (adapted from [@b0285]), (e) nanocomposite (adapted from [@b0715]), (f) composite nanofiber (adapted from [@b0400]), (g) nanoparticles (adapted from [@b0615]), (h) polymeric nanofibers (adapted from [@b0260]), (i) antibiotic nanoparticles (adapted from [@b0525]) and (j) antibiotic nanocomposite (adapted from [@b0160]).

The development of taste masked formulations is of importance in the pharmaceutical companies as this enhances patient compliance ([@b0715]). The effectiveness of an ethylcellulose polymer (Ethocel™ 100 in the case) used in conjunction with other polmyeric materials as a taste-mask coating for very bitter Quinine, a known anti-malarial agent, was reported by [@b0715]. These formulations were developed in the form of nanocomposite particles ([Fig. 2](#f0010){ref-type="fig"}(e)) by spray drying using a two-solution mixing nozzle. In addition to the taste masking effect, the nanocomposite regulated the intestinal absorption of quinine ([@b0715]) which was also partly due to the presence of an ethylcellulose polymer within the composite matrix. A study compared the dexamethasone release characteristics from ethylcellulose-based nanoparticles (Ethocel™ standard 4 premium) with other carriers namely Eudragit® RS100 and mixture of lipids. Overall, the EC nanoparticle display the most extended release behaviour ([@b0065]). In 2017, Balzus and co-workers also demonstrated that ethylcellulose improved the encapsulation efficiency/loading capacity of dexamethasone containing nanoparticles compared to Eudragit® while a combination of these two polymeric excipients yielded a drug-nanoparticulate matrix with maximized loading capacity, minimal toxicity, controlled dexamethasone release and mucosal permeation ([@b0070]). Besides, [@b0605] applied the taste masking and slow release properties of ethylcellulose as a coating to the formulation of Gabapentin nanosponge-based controlled release, reconstitutable dry suspension for use in paediatric patients using the suspension layering technique.

The work of [@b0400] showed that the inclusion of ethylcellulose as a matrix former potentially improved mechanical properties of the entire delivery system. In this case, ethylcellulose was co-electrospun with zein (a key corn protein) to prepare a water-stable composite nanofibre formulation loaded with a non-steroidal antiinflammatory drug, indomethacin ([Fig. 2](#f0010){ref-type="fig"}(f)) which demonstrated sustained, diffusion-controlled release behaviour. Nimesulide release from ethylcellulose nanoparticles ([Fig. 2](#f0010){ref-type="fig"}(g)) prepared using the desolvation approach was slowed down and sustained relative to methylcellulose which was also tested under similar conditions. Heamatotoxicity studies also confirmed the compatibility of the ethylcellulose with blood cells attributable to the non-toxic nature of ethylcellulose polymers ([@b0615]). Similarly, [@b0260] demonstrated the biocompatible and extended release properties of ethylcelluose as it was employed in the architecture of polymeric nanofibers loaded with ketoprofen for tissue engineering and drug delivery applications ([Fig. 2](#f0010){ref-type="fig"}(h)). Amorphous nanocapsules of beclomethasone dipropionate were prepared for pulmonary delivery using ethylcellulose. Interestingly, these nanocapsules displayed encapsulation efficiency close to 100%, delayed photodegradation of pharmaceutical active, prolonged release without burst effect and insignificant cytotoxic effect ([@b0120]).

Nanoencapsulation of pharmaceutical actives using ethylcellulose has been shown to enhance antibacterial activity and minimize toxicity. Park and team reported the formulation of an antibiotic ethylcellulose nanofiber which demonstrated desirable antibiotic release trends with optimal and sustained antibacterial efficacy against Staphylococcus aureus as opposed to administering the antibiotic alone ([@b0535]). Encapsulation of clarithromycin into ethylcellulose (viscosity 250--300 cP, ethoxy content 48%) nanoparticles ([Fig. 2](#f0010){ref-type="fig"}(i)) for the treatment of four strains of *Helicobacter pylori* infection *in vivo* in murine models exhibited significantly improved antibacterial activity. Ethylcellulose encapsulation did not only enhance the anti-adhesion activity of clarithromycin but also significantly enhanced *H. pylori* clearance within the stomach of the infected murine model ([@b0525]). Likewise, encapsulation of rifampicin with ethylcellulose (100 cP) was achieved using the supercritical anti-solvent process. Co-precipitation of ethylcellulose with rifampicin resulted in the formation of well encapsulated, drug loaded nanocomposites of diameters ranging between 190 and 230 nm ([Fig. 2](#f0010){ref-type="fig"}(j)). In addition to improving rifampicin's encapsulation potential, its release was prolonged and bioavailability potentially improved ([@b0160]). Furthermore, [@b0200]) investigated the potential of ethylcellulose-based nanoparticles in modulating the release kinetics and minimizing the ulcerogenic effect of piroxicam following oral administration. Nanoparticles were prepared in combination with other stabilizers added at different concentration using the evaporation technique and *in vivo* testing in rats showed a reduction in the mean ulcer index.

6. Macro-structured delivery systems fabricated from ethylcellulose polymers {#s0030}
============================================================================

Here, drug containing delivery systems or carriers with geometrical dimensions that fall outside the nano- and micro- meter ranges are discussed. These will include but not limited to tablets, films, capsules and phase transitional gels.

6.1. Diversified tablets {#s0035}
------------------------

The oral route of drug administration remains the most preferred in patient care and tablets are the most common commercially available and acceptable oral preparation. Tablets with extended release characteristics are often more desirable especially for chronic conditions because they offer better patient compliance, consistent plasma drug levels, reduced dose (frequency and amount) and side effects as well as increased safety margin of high-potency drugs ([@b0075], [@b0610]). Considering the hydrophobic nature of ethylcellulose polymers, they have found extensive use in the fabrication of different drug-loaded tablets for improving the desired pharmacotherapeutic effects ([@b0175], [@b0180], [@b0235]).

Studies have reported their use as semipermeable membranes either as single entities or in combination with other polymeric biomaterials in the preparation of osmotic tablets. They function by regulating the influx and efflux transfers of surrounding aqueous and drug molecules as well as control the disintegration kinetics of monolithic osmotic pump tablets ([@b0035], [@b0375], [@b0370], [@b0390]), bilayer-core osmotic pump tablet ([@b0390]) ([Fig. 3](#f0015){ref-type="fig"}(a)) and pulsatile core tablets ([@b0385]). The have also been found to minimize burst effect, function as release retardants and hydrophobic coatings in elementary osmotic pump tablets ([@b0030], [@b0050], [@b0515]) and osmotic drug delivery systems ([@b0550]) respectively.Fig. 3Ethocel™ polymer based: (a) osmotic tablet (adapted from [@b0395]), (b) 3-D printed tablet (adapted from [@b0765]), (c) gastroretentive tablet (adapted from [@b0140]), (d) mini-matrix tablets (adapted from [@b0215]), (e) mini-tablet (adapted from [@b0460]) dosage forms.

Ethylcellulose polymers have found use as matrix formers and release extenders in oral tablet formulations ([@b0440], [@b0560]). 3D printed tablets of ibuprofen with internal scaffolding structure ([Fig. 3](#f0015){ref-type="fig"} (b)) elicited sustained release characteristics associated with the inclusion of ethylcellulose standard 10 which was first fused and then extruded in filaments with other excipients by hot melt extrusion. The resulting filaments were printed into extended release tablets by fused deposition modelling ([@b0765]). In 2015, Nour and colleagues formulated an optimized microspheres in compressed tablet of bumadizone calcium dihydrate for colon targeting and controlled release. Their findings showed that microspheres based on ethylcellulose N100 displayed the highest entrapment efficiency which was attributed to its higher viscosity and ability to decrease drug diffusion to the outer phase increasing retention within the microsphere core as well as extended *in vitro* and *in vivo* release behaviour ([@b0495]). The drug release retarding properties of ethylcellulose also found application in the construction of a once-daily dosing sustained release coated tablet of tolterodine-L-tartrate in the management of overactive bladder. This preparation compared well with the commercially available slow release formulation utilizing generated pharmacokinetic information ([@b0585]). [@b0110] developed diltiazem hydrochloride matrix tablets by direct compression coupled with thermal treatment and ethylcellulose N22 plus polycarbophil were employed as the matrix forming polymer. Tablet were stable and displayed a zero order prolonged release behaviour typified by anomalous transport mechanisms.

Research has shown ethylcellulose polymers to be valuable excipients for the construction of pulsatile tablets demonstrated by the work done by [@b0665] which detailed the optimization of a valsartan-loaded tablet designed to coordinate release dependent on the circadian rhythm. Ethylcellulose was shown to play a significant role in the modulation of the lag time and time taken for 90% of the drug to be released ([@b0665]). This was also established by [@b0540] where ethylcellulose-based coated-tablets of prednisone prepared by direct compression exhibited pulsatile release envisaged to facilitate the management of chronological disorders such as asthma. The efficacy of ethylcellulose as a release modulator was maintained but significantly influenced by the nature of other incorporated adjuvants. These pulsatile release tablets were further tested as carriers for other drugs namely methylprednisolone, diclofenac sodium, diltiazem hydrochloride, nifedipine and lornoxicam which displayed robust release trends ([@b0545]).

The versatility of the Ethocel™ polymers have also being displayed in their use as the only excipient or co-excipients in the development of specialty tablets designed for specific physiological target sites. Amongst these are the gastroretentive tablet matrices based on novel floating, high density, bioadhesive or swellable delivery technologies for improving the absorption and pharmacotherapeutic benefits of bioactive molecules ([@b0080]). They have been utilized as release retardants ([@b0450]), combination coats ([@b0140]) and matrix forming agents ([@b0685]) in gastroretentive tablet formulations ([Fig. 3](#f0015){ref-type="fig"}(c)). [@b0555]) documented its performance as an effective mucoadhesive coat for the localized oral cavity delivery of fluconazole in a tablet preparation for oral thrush treatment. Another interesting contribution was that reported by [@b10000] and [@b0340] detailing their role, in conjunction with model Eudragit polymers, as coating and release sustaining agents in the design of colon-targeted delivery systems.

Mini-tablets are a single or multiple unit dosage form with a diameter of ≤6 mm composed of one or more excipients ([@b0215]). Ethocel™ standard 100 premium was employed as part of the core component, coating and stability enhancer for a mini-tablet containing venflaxine hydrochloride. As a coating, Ethocel™ 100 extended the release of venflaxine from the mini-tablets but as a core component, it surprisingly enhanced rapid drug release which the authors attributed to polymer migration towards the surface and pore formation through the coat ([Fig. 3](#f0015){ref-type="fig"}(d)). Furthermore, a direct relationship between the thickness of the coat and prolonged venflaxine release capacity was observed for the minitablets ([@b0215]). Ethylcellulose-based mini-tablets formulation loaded with theophylline were studied by [@b0460] ([Fig. 3](#f0015){ref-type="fig"}(e)). In this case, Surelease®, an aqueous ethylcellulose grade was employed as a film coating for the mini-tablets which displayed a prolonged theophylline release characteristics. Additionally, an increase in the Surelease® coating weight and a reduction in hydrophilic constituent levels within the mini-tablet matrices resulted in well-tailored, delay in lag and release times ([@b0460]). Besides, ethylcellulose 100 cps was indicated in the construction of sustained release matrix type ocular minitablets containing timolol maleate for glaucoma treatment. Amongst other tested formulations, the ethylcellulose containing matrix was selected as the optimal preparation and it demonstrated a zero-order release kinetics with well-sustained timolol release patterns ([@b0465]). Recently, [@b0365], [@b0380] also reported their work focused on employing ethylcellulose as a release-modifier for quetiapine fumarate containing mini-matrix prepared by hot melt extrusion.

6.2. Macrocapsules {#s0040}
------------------

Macrocapsules can also be referred to as capsules and they are often used as a macro-sized encapsulating shell for active pharmaceutical ingredients generally for oral administration. Different types of capsules with shells prepared from different biocompatible materials (e.g. gelatin, hypromellose) exist and are used for different purposes within the pharmaceutical industry ([@b0085]). Ethocel^TM^ polymers have been applied in different ways to enhance the performance of oral macrocapsules. An example of this is the work reported by [@b0730]) whereby ethylcellulose was employed in the fabrication of cinnarizine-loaded films which were then folded in different patterns into hard gelatin capsule shell to form a compressed device for gastroretentive drug delivery. The polymeric film displayed an initial burst followed by a well-controlled non-Fickian diffusion pattern suitable for its intended application. Research has also shown the application of ethylcellulose as a body and cap in the development of an oral capsule delivery system which rapidly ejected incorporated payload of bioactives within the small intestine to improve bioavailability and efficacy ([@b0740]).

6.3. Transdermal and topical platforms {#s0045}
--------------------------------------

The skin extends over a large total surface area of the body which is approximately 1.8 m^2^ and functions as the main contact between the human body and its surroundings ([@b0245]). Delivery of drug molecules to the skin is mainly categorized as *dermal* referring to the process of mass transport of bioactives applied to the skin surface into various skin layers and the *transdermal* which encompasses the entire process of absorption of drug molecules from the skin surface (point of application) through each layer of the skin leading to their uptake by the skin microcirculation system and final distribution into the blood stream ([@b0230], [@b0245]). Studies have detailed the effectiveness of ethylcellulose polymers as polymeric templates for drug delivery to the skin ([@b0565]). [@b0100] confirmed this through their work focused on development of ethylcellulose microsponge gel for the topical delivery of eberconazole nitrate employing a quasiemulsion solvent diffusion method ([Fig. 4](#f0020){ref-type="fig"}(a)). The presence of ethylcellulose in the matrix facilitated controlled drug release and cutaneous deposition which aided non-toxic fungal therapy. Research reports have also documented the performance of ethylcellulose polymers in the presence of other adjuncts as matrix materials for transdermal patches designed for the systemic delivery lipophilic flurbiprofen ([@b0275]) and dexibuprofen ([@b0025]). In this case, the ethylcellulose patches variant showed the most desired permeation enhancing and flexible characteristics. Furthermore, a multidrug transmucosal drug delivery systems displaying complex release properties was developed by [@b0490] for use as a preoperative anesthetic and analgesic during dental surgical procedures ([Fig. 4](#f0020){ref-type="fig"} (b)). Ethylcellulose viscosity 20 (50% ethoxy content) functioned as a backing layer for this system which demonstrated prolonged combined anesthetic and analgesic effects. Further enquiries by [@b0630] also confirmed the efficiency of ethylcellulose as a biocompatible backing layer for a mucoadhesive bi-layered strip for controlled delivery of lidocaine. Interestingly, Ethocel^TM^ polymers have also being indicated in the formulation of transdermal sprays for clotrimazole as an attempt to improve its *in vivo* antifungal performance ([@b0530]).Fig. 4Ethylcellulose (a) microsponge gel for topical delivery (adapted from [@b0100]), (b) anesthetic and analgesic loaded transmucosal patch (adapted from [@b0490]), (c) buccal disc for oromucosal drug delivery (adapted from [@b0770]), (d) timolol maleate-brimonidine tartrate ocular inserts (adapted from [@b0620]), (e) in situ forming gel containing antimicrobials (adapted from [@b0575]).

6.4. Film constructs and discs {#s0050}
------------------------------

The utilization of ethylcellulose polymers alone or in conjunction with other adjuvants in the preparation of useful film-like drug carriers is well documented in recent times ([@b0155], [@b0355], [@b0660], [@b0770], [@b9000], [@b0815]). Amongst other drug delivery applications are their use in the construction of buccal films for delivery within the oral cavity. This was evidenced through a study reported by Laffleur and team where ethylcellulose 10 cP was applied in combination with other pharmaceutical additives for the preparation of robust allantoin-loaded films for the management of dry mouth syndrome has been demonstrated. The findings showed that the produced films were functional, mucoadhesive, flexible and stable with great promise for treating various intraoral cavity diseases ([@b0355]). A related study reported ethylcellulose functioning as a backing sheet for bilayered mucoadhesive buccal films containing a combination of ornidazole and dexamethasone prepared for treating oral ulcers. *In vivo and in vitro* observations showed positive effect on mucosal repair plus reduced ulcerations and inflammation ([@b0805]). In a similar way, fluticasone propionate was formulated for localized buccal delivery through a mucoadhesive buccal film formulation composed of ethylcellulose and other polymeric blends. Films based on ethylcellulose were selected as the best performing with desirable sustained release characteristics and potential therapeutic efficacy ([@b0040]).

Beyond buccal films, ethylcellulose-copovidone three layered thin oral film preparations containing three antihypertensive agents (hydrochlorothiazide, amiloride hydrochloride and carvediol) were printed using three course jet dispensing technology. The role of ethylcellulose as a release modifier was noticeable and the developed film can be used as personalized formulation for the delivery of combination drugs ([@b0660]). Building upon this, ethylcellulose in conjunction with *propolis* extract (BP) were developed into modified release films for the controlled liberation of metronidazole for the treatment of protozoa and anaerobic bacteria infections. Results showed that in addition to release modification, the film formulation protected the metronidazole molecules ([@b0155]). Investigations directed towards their use as mucoadhesive buccal discs for oromucosal delivery ([Fig. 4](#f0020){ref-type="fig"}(c)) have also been recorded where ethylcellulose together with polyethylene glycol derivatives facilitated prolonged release of corticosteroids and/or anesthetics for effective treatment of recurrent aphthous stomatitis ([@b0770]). Furthermore, ethylcellulose together with Eudragit S100 and other hydrophilic polymers like polyvinyl alcohol were optimized and developed into biocompatible reservoir type triple-layered ocular inserts ([Fig. 4](#f0020){ref-type="fig"}(d)) for dual release timolol maleate and brimonidine tartrate intended for the management of glaucoma. Again, the ethylcellulose layer within the inserts served as the rate controlling membrane and extended drug release for up to 32 h *in vitro* ([@b0620]).

6.5. Emulsions, colloids, dispersions and gels {#s0055}
----------------------------------------------

In the formulation of semi-solid dispersions such as emulsions and gels, which are considered as fluid delivery systems, Ethocel™ polymers have been majorly applied as flow modifiers in the form of release extenders considering their water insoluble nature ([@b0655]). Ethylcellulose combined with glycerylmonooleate served as release sustaining carrier platforms for metronidazole in the form of mucoadhesive gels intended for periodontal application. Drug release followed the Fickian diffusion mechanism and a direct relationship between drug loading dose and release patterns was observed ([@b0655]). Other findings detail its function in the design of solvent exchanged *in situ* gel forming delivery system for antimicrobials ([Fig. 4](#f0020){ref-type="fig"}(e)) indicated in the treatment of periodontitis ([@b0575], [@b0695]). Ethylcellulose played a major role controlling the viscosity of these systems and their abilities to exhibit optimized flow properties which directly influenced their sustained drug release behavior required for their intended periodontal applications ([@b0575]).

Sun and colleagues reported the role of ethylcellulose as a matrix former in a Eudragit S100, castor oil, cremophor RH40, and 1,2-propylene glycol mix for the preparation of solid, micro-structured emulsified delivery systems containing osthole, a clinically applicable hydrophobic coumarin compound. Initially, a liquid osthole loaded self-microemulsifying delivery system was formed and this was transformed into a solid form through the application of the spherical crystallization technique. Interestingly, the more stable solidified micro-emulsified system retained its initial morphology, particle size and zeta potential as when in the liquid state and ethylcellulose remained functional as a matrix former and release extender evidenced through the *in vitro*/*in vivo* studies ([@b0710]). 51% w/w ethoxyl content ethylcellulose nanodispersions were prepared using a facile method involving its dissolution in ethanol and subsequent dipping in xanthan gum solution as an anti-solvent. The nanodispersions functioned as stable, non-toxic effective stabilizers for drug loaded oil-in-water pickering emulsions ([@b0745]). Another investigation by [@b0090] also reported the use of ethylcellulose colloidal nano-suspensions as stabilizers for foams and emulsions through mechanisms related to interfacial particulate interactions coupled with energy absorption and surface tension transitions. Overall, particulate stabilization of foams and emulsions has been the focus of several studies because they have been found to be more stable compared surfactant stabilized ones.

6.6. Beads, granules and pellets {#s0060}
--------------------------------

Researchers have also widely utilized ethylcellulose polymers as carrier templates for drugs and bioactives engineered in the form of nano- or micro-structured multiparticulates such as beads, granules and pellets ([@b0250], [@b0755], [@b0760]). As an ofloxacin-loaded floating bioadhesive multiparticulate delivery system ([Fig. 5](#f0025){ref-type="fig"}(a)), ethylcellulose in the form of Surelease® E-7-19040 combined with Eudragit® NE 30D were used to achieve optimal weight gain for robust pellet core structures and as coating which aided an extended release characteristic ([@b0800], [@b0810]). [@b0475] developed multi-layered pellet delivery systems ([Fig. 5](#f0025){ref-type="fig"}(b)) for different model drugs with different solubility values which aided comprehension of their release kinetics and mechanisms. Ethylcellulose aqueous dispersion NF (Aquacoat®) was employed as an external coat layer and it was discovered that amongst other applied excipients layers, it was dominant for exhibited sustained release characteristics, minimized potential effects of pellet core type and nature of the surrounding bulk fluid.Fig. 5(a) Morphological differences exhibited by Ethocel™ based (a) ofloxacin-loaded floating bioadhesive multiparticulate delivery system (adapted from [@b0800], [@b0810]), (b) multi-layered pellets (adapted from [@b0475]), (c) tacrolimus containing extended release granules (adapted from [@b0720]), (d) rough surfaced pellets (adapted from [@b0590]), (e) osmotic theophylline pellets (adapted from [@b0325]), (f) reservoir type extended release multiparticulates (adapted from [@b0210]), (g) wax based floating sustained-release dispersion pellets (adapted from [@b0755]).

[@b0135] also presented their findings which explored ethylcellulose as a binding agent for the formulation of doxorubicin and metronidazole loaded bioactive mesoporous silica granular formulations useful for localized bone treatment and regeneration purposes. Key findings by [@b0720] documented the performance of ethylcellulose standard 10 FP, as a release extender and solubility enhancer for poorly water-soluble tacrolimus formulated as extended release granules ([Fig. 5](#f0025){ref-type="fig"}(c)) intended to potentially prevent allograft rejection through *in vitro* investigations. *In vivo* experiments confirmed these outcomes as a sustained absorption of tacrolimus was observed male cynomolgus monkeys. Another study further supports this finding as an ethylcellulose film layer/coating over the pellet formulation ([Fig. 5](#f0025){ref-type="fig"}(d)) slowed down drug release rate while an increase in the thickness of this layer increased the lag time even more ([@b0590]). It was noted that the surfaces of the pellets were rough and polyvinylpyrrolidone was used as a co-excipient to reduce pellet surface roughness. Interestingly, ethylcellulose film formation was improved and led to a more pronounced retardation of drug release from the pellets. As a release sustainer and bioavailability enhancer, ethylcellulose derivatives have been indicated as key adjuncts in the architecture of various multiparticulate drug delivery species which include matrices of theophylline ([@b0010]), osmotic theophylline pellets ([Fig. 5](#f0025){ref-type="fig"}(e)) ([@b0325]), capsaicin matrix pellets ([@b0800]), osmotically active glucose pellets ([Fig. 5](#f0025){ref-type="fig"}(f)) ([@b0210]), metoprolol tartrate and acetaminophen reservoir type extended release dosage form ([@b0445]), steroid hormone composite pellets ([@b0250]), oral time-controlled release etodolac pellets ([@b0805], [@b9000]), glipizide beads ([@b0485]) and atenolol pellets ([@b0405]).

In addition, studies have documented the application of ethylcellulose-based multiparticulate carriers for the targeted delivery of bioactives for eliciting specific pharmacological effects. An example was the investigation reported by [@b0750] whereby colon adhesive pellets of 5-aminosalicyclic acid were prepared as an oral modified release delivery system to minimize the side effects associated with systemic absorption for the treatment of ulcerative colitis. In this case, Surelease®, an ethylcellulose variant functioned as an inner layer for waterproofing and extended release. Surelease® was also applied as a release rate modulator in pH sensitive pellets intended for effective colon-targeted delivery of capecitabine to avoid frequent high dosing and associated systemic adverse effects ([@b0520]). Another investigation employed ethylcellulose together with pectin as a coating for oral minispheres that regulated ciclosporin release kinetics within the small intestine, enhanced delivery and uptake in the colon of the porcine model employed indicating improved clinical advantages in the treatment of inflammatory conditions of the large intestines ([@b0335]). [@b0755] also presented a study focused on the development of wax based floating sustained-release dispersion pellets ([Fig. 5](#f0025){ref-type="fig"}(g)) containing protocatechuic acid for localized timed gastric residency to improve its bioavailability and desired therapeutic performance. Ethylcellulose 100 cP was used as the coating which resulted in efficient sustained drug release activity of 12 h based on non-Fickian transport mechanisms. Extended release ibuprofen enteric coated pellets were successfully designed for small intestine delivery and ethylcellulose served as a water impermeable sustained release membrane. Optimized pellets demonstrated prolonged release characteristics comparable to commercially available ibuprofen preparations both *in vitro* and *in vivo* in beagle dogs ([@b0165]).

6.7. Implantable structures {#s0065}
---------------------------

Implantable structures are promising bioactive carriers that have been used for many biomedical purposes especially for the delivery of drugs that are not efficiently bioavailable when administered via the oral route or when site-specific dosing is important to patient care ([@b0780]). They are usually capable of providing long-term stability, controllability, biocompatibility and extended release kinetics with minimal side effects ([@b0295], [@b0780]). With Ethocel™ premium polymers being hydrophobic and mechanically strong in nature, they have found good use in the design of drug loaded implantable structures such as the osmotically driven remote-controlled magnetic nanocomposite membranes fabricated in 2015 by Zaher and colleagues. These membranes were based on either ethylcellulose or in some instances stronger cellulose acetate polymers mixed with thermosensitive poly (N-isopropylacrylamide) hydrogel and superparamagnetic iron oxide particles. The ethylcellulose containing prototype membrane devices had drug diffusion rates on the order 0.5--2.0 μg/h for higher release and 12--40 ng/h for lower release kinetics ([@b0780]). Ethocel™ standard 45 Premium showed desirable performance in the construction of quinine loaded implants [Fig. 6](#f0030){ref-type="fig"}(a) using the 3D printing technique of fused deposition modeling®. This work employed other polymers namely Eudragit®RS, polycaprolactone, poly(L-lactide) but the ethylcellulose based implant displayed the lowest prolonged release kinetics of 5% quinine over 100 days ([@b0330])*.* Additionally, ethylcellulose 24--27 cP formed a major backbone for a timolol maleate loaded implantable nanoparticle-laden ring-in-hydrogel contact lenses ([Fig. 6](#f0030){ref-type="fig"}(b)) that was reported to provide controlled delivery kinetics at therapeutic rates without compromising critical contact lens properties for the management of glaucoma. *In vitro* release kinetic data showed sustained drug release within the therapeutic window for 168 h with a 150 μg timolol maleate loading. The implant was well tolerated displaying insignificant cytotoxicity and ocular irritation while *in vivo* pharmacokinetic studies in rabbit tear fluid indicated a substantial elevation of the mean residence time and area under curve with therapeutic efficacy comparable to conventional eye drop therapy. Furthermore, *in vivo* pharmacodynamic information showed a sustained reduction in the ocular pressure of a rabbit model for 192 h ([@b0435]).Fig. 6(a) Quinine loaded implantable matrix (adapted from [@b0330]), (b) hydrogel contact lenses for controlled drug delivery (adapted from [@b0435]), (c) localized sustained release varnishes of thiazolidinedione-8, (adapted from [@b0680]) and (d) chlorhexidine sustained-release varnishes for catheter coating (adapted from [@b0220]) based on Ethocel™ polymeric derivatives.

6.8. Sustained-release varnishes {#s0070}
--------------------------------

Researchers have described varnishes as sustained release delivery systems that differ in their performances based on the nature of the polymer matrix, other pharmaceutical additives and therapeutic agents. They are capable of forming film structures which occur through physicochemical transitions within the polymeric chains and their mechanisms for controlled release are usually diffusion and erosion. Among the most widely used polymers for developing varnishes are the ethylcellulose and vinyl acetate-acrylate copolymers ([@b0670], [@b0680], [@b0700]). [@b0680] reported ethylcellulose N-100's role in the development of local sustained release varnishes of an anti-quorum-sensing molecule, Thiazolidinedione-8, that has the potential to effectively prevent catheter-associated urinary tract infections, a major healthcare challenge. The thickness of the film and presence of other excipients were the main factors that affected drug release mechanisms based on the Higuchi model. The drug loaded ethylcellulose-based formulation displayed good retention for 8-days on both latex and silicon catheters and demonstrated activity against *Candida albicans* biofilms ([Fig. 6](#f0030){ref-type="fig"}(c)). A similar ethylcellulose N-100 varnish formulation designed for the prolonged delivery of chlorhexidine. They were particularly developed for application as catheter coatings for anti-biofilm activity of *Pseudomonas aeruginosa* ([Fig. 6](#f0030){ref-type="fig"}(d)). Chlorhexidine release was by diffusion and the varnish coating were retained on siliconized latex Foley catheters for at least 2 weeks and showed extended activity in a biological medium ([@b0220]). Ethylcellulose varnish formulations containing chlorhexidine were also applied to ureteral stents to minimize urinary tract bacterial colonization and proliferation on the stent surface. They effectively prolonged growth inhibition of *Enterococci*, *Pseudomonas*, and *Escherichia coli* for between 1 and 2 weeks ([@b0790]).

6.9. Elastomerics {#s0075}
-----------------

Patients undergoing orthodontic treatment are usually prone to plaque build-up around their appliances and enamel demineralization around their brackets because oral hygiene is more difficult for these patients ([@b0300]). Consequently, [@b0300], [@b0305]) applied extended drug release principles to improving delivery efficiency to the particular target sites. In 2015, they developed chlorhexidine-releasing elastomerics using ethylcellulose because of it proven safety, oral cavity efficacy and release extending qualities. An extended chlorhexidine release of 48 h and continued antibacterial effect on *streptococcus mutans* over this period was observed ([@b0300]). In 2017, Jeon and colleagues reported further performance enhancements for the extended release chlorhexidine elastomerics by applying a layer-by-layer approach using an ethylcellulose coat. Surprisingly, this extra ethyl cellulose coat significantly prolonged chlorhexidine release and antimicrobial efficacy for 7 days ([@b0305]).

6.10. Transungal delivery systems {#s0080}
---------------------------------

Ethylcellulose has been indicated in the synthesis of a lipophilic matrix-based system of isotretinoin in the form of a nail lacquer intended for the treatment of nail psoriasis. This topical lacquer formulation was designed to form a film over the nail plate after the evaporation of solvent contained in the formulation. Drug delivery form the formed film was based on the existence of a drug concentration gradient that resulted in slow, penetrating release patterns through the nail plate. Ethylcellulose served as a biocompatible viscosity and release modifier for this formulation and compared well with commercially available Retino-A cream marketed preparation of 0.05%w/w isotretinoin. The nail lacquer was reported to show extensive distribution across the human nail plate model 72 h post application in comparison with the control formulation ([@b0315]).

7. Premium ethylcellulose polymers function as carriers for biologics and botanicals {#s0085}
====================================================================================

Though not very common, Ethocel™ polymers have also being shown to function as robust platforms for loading and rate-modulated delivery of biologicals and botanicals. Such smart carrier systems are of different functional modalities ranging from nano- to micro- to macro- templates for different therapeutic uses ([@b0255], [@b0280]). Standard ethylcellulose was used in combination with pectin, sodium alginate, calcium chloride, span 80 in the fabrication of enteric double coated microparticles of Biochanin A, a phytoestrogen isolated from *Trifolium pratense* that exert estrogenic effects and causes vasodilation and decrease in pro-inflammatory mediators, employing the ionotropic external gelation and coacervation phase separation coating method. Ethylcellulose was reported to aid release extension and improve oral bioavailability of poorly soluble Biochanin A by preventing stomach degradation ([@b0645]). Likewise, solid-lipid nanoparticles containing Morin (3,5,7,2′,4′-pentahydroxyflavone), a flavonoid from fruits, vegetables and tea were prepared from 49%w/w ethoxyl content Ethylcellulose 45 together with Witocan® H, Tween 60, polyvinyl alcohols using heated homogenization and evaporation. Ethylcellulose functioned as a release sustainer and overall, the formulation displayed improved oral bioavailability, aqueous solubility and minimized premature bioactive degradation ([@b0280]). Still on botanicals, [@b0650]) developed ethylcellulose-based nanoparticles loaded with a plant-based flavonoid, Quercetin, for topical application in skin cancer chemotherapy utilizing the process of nanoprecipitation. In this formulation, ethylcellulose acted as a reservoir in skin ducts and furrows because of it biocompatibility and non-biodegradability and consequently aided bioactive retention and controlled release kinetics that can enhanced penetration through skin layers for treatment of skin cancer.

Additionally, biologicals such as L-alanyl-L-glutamine peptide effective in promoting acute glycemia recovery during long-term insulin-induced hypoglycemia have been encapsulated in standard premium ethylcellulose NF 20 microparticles by emulsification/hardening and solvent evaporation techniques. Ethylcellulose was shown to improve biocompatibility, formulation flexibility and overall prolonged peptide release to promote acute glycemia recovery and effective oral administration ([@b0735]). [@b0255] encapsulated a dairy-derived hydrolysate, FHI-2571 know as a peptidic ghrelin agonist into pellet formulations made up of Ethocel™ standard 20 premium, methacrylic acid copolymer and microcrystalline cellulose utilizing dry blending combined with wet granulation, spheronization and drying. The presence of an ethylcellulose variant within the formulation mechanically strengthened the matrix, modified release kinetics and served as an external protective coat. Development of this formulation enabled oral dosing, *in vivo* performance and potential application in paediatric and geriatric patients ([@b0255]). Moreover, [@b0675] developed enteric coated nanosized emulsion capsules of cyclosporine A, an immunosuppressing cyclic polypeptide using Standard ethylcellulose, maize oil, oleic acid, Tween 20 and polyethylene gloycol 400 processed using homogenization coupled with macro-encapsulation. Ethylcellulose within this carrier system worked as a water insoluble membrane, primary/deep coating enhancing it's colon targeting for better management of local intestinal pathologies.

8. Conclusions {#s0090}
==============

Premium ethylcellulose polymers are biomaterials of noticeable value within the pharmaceutical and biomedical spheres. They function as excellent biocompatible excipients suitable for the architecture of a wide variety of active pharmaceutical ingredients which are transforming the face of medicines and improving human well-being globally. This has been evidenced through extensive *in vitro* and *in vivo* tests documented through scientific investigations as discussed. EthocelTM polymers are flexible and easy to process alone or with other excipients employing different re-fabrication techniques useful for the development of novel drug carriers. They usually function as release extenders, external coating, flexibility enhancers and mechanical strengtheners. They are typically tasteless, colorless, odorless, non-caloric and inert within the physiological environment, making them even more attractive for biomedical and pharmaceutical industrial applications. They are used as carriers for small drug molecules but enjoy limited use as delivery templates for botanicals and larger bioactive molecules like peptides. Considering their inertness, biocompatibility and stability at extreme temperatures, there is the need to expand their application towards the development of rate-modulated delivery systems for structurally larger biological molecules.
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